Evacetrapib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiovascular Disease
Conditions
Cardiovascular Disease
Trial Timeline
Apr 1, 2013 → Oct 1, 2013
NCT ID
NCT01825889About Evacetrapib
Evacetrapib is a phase 1 stage product being developed by Eli Lilly for Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01825889. Target conditions include Cardiovascular Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02497391 | Phase 1 | Completed |
| NCT02226653 | Phase 1 | Completed |
| NCT02168803 | Phase 1 | Completed |
| NCT01903434 | Phase 1 | Completed |
| NCT01825889 | Phase 1 | Completed |
| NCT01836185 | Phase 1 | Completed |
| NCT01810432 | Phase 1 | Completed |
Competing Products
20 competing products in Cardiovascular Disease